We also performed a large-scale, case-control study of the association of the APOBEC3B deletion with breast and ovarian cancer in three different European cohorts (encompassing >6500 samples), which revealed the lack of association of the APOBEC3B deletion with breast and ovarian cancer in European populations. Here, APOBEC3B is linked to ovarian carcinoma.